Accessibility Menu
Septerna logo

Septerna(NASDAQ) SEPN

Market Cap$1.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+72%
5 YearN/A
1 Year+160%
1 Month-5%
$36.75
-0.14%
-0.05Today
Septerna last closing stock price
MetricPriceDate
Last closeUSD 36.752026-09-04
Septerna stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.55%USD 38.912026-08-28
1 month-5.19%USD 38.762026-08-05
3 month+17.98%USD 31.152026-06-05
Year to date+31.81%USD 27.882025-12-31
1 year+160.27%USD 14.122025-09-04
Since inception+71.73%USD 21.402024-10-25

Septerna Financials at a Glance

Market Cap

$1.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$98.88M

Net Income (TTM)

-$24.24M

EPS (TTM)

-$0.54

P/E Ratio

-67.56

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Price

$36.75

Volume

199,666.722

Open

$36.57

Previous Close

$36.75

Daily Range

$36.57 - $37.59

52-Week Range

$13.67 - $51.10

Estimated Earnings Date

Nov 9, 2026

SEPN News

SellAlert-Red.png

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

Robert IzquierdoJul 5, 2026
SellAlert-Purple.png

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

Cory RenauerJun 29, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Septerna

Septerna, Inc. helps people with hormone and metabolic diseases. The company creates pills to replace complex injectable treatments. Its technology helps scientists find drugs for specific cell receptors.

Transforming Medicine With Pills

  • SEP-479 PTH1R Agonist: Oral pill for treating hypoparathyroidism; currently in Phase 1 clinical trials to test safety and dosing.
  • SEP-631 MRGPRX2 NAM: Therapy designed to lower the activity of specific immune cells; currently undergoing strategic evaluation for various mast cell diseases.
  • TSHR Program: Potential oral treatment for Graves’ disease and thyroid eye disease; currently in the discovery stage.
  • Partnered Metabolic Programs: Joint development with Novo Nordisk targeting weight loss and metabolic conditions; includes a GIP receptor agonist to trigger biological responses.

Strategic Partnerships and Expansion

  • Entered a global partnership with Novo Nordisk in May 2025 to develop oral metabolic therapies.
  • Received a $195.0 million upfront nonrefundable payment as part of the Novo Nordisk collaboration in July 2025.
  • Delivered the first development candidate to Novo Nordisk in July 2026.
  • Established an at-the-market offering program in March 2026 to sell up to $150.0 million in stock.

What Makes the Technology Unique?

The Native Complex Platform replicates the natural shape of G protein-coupled receptors, which are proteins on cells that act as biological sensors. This technology identifies oral medicines for targets that typically require patients to use frequent injections.

Recent Financial Performance

  • Total revenue was $53.3 million for the six months ended June 30, 2026.
  • Net loss was $21.7 million for the six months ended June 30, 2026.
  • Market capitalization was $1.5 billion in Q2 2026.
  • Cash and marketable securities totaled $516.5 million as of June 30, 2026.

Bottom Line

Septerna has evolved from a research-focused startup into a clinical-stage biotechnology firm with a major global partner. Its focus on oral drugs aims to modernize the treatment of chronic metabolic and endocrine disorders.

AI Generated • Aug 11, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

123

CEO

Jeffrey T. Finer, MD, PhD

Website

www.septerna.com

Headquarters

South San Francisco, CA 94080, US

SEPN Financials

Key Financial Metrics (TTM)

Gross Margin

99.57%

Operating Margin

-44.04%

Net Income Margin

-24.51%

Return on Equity

-6.31%

Return on Capital

-19.92%

Return on Assets

-4.28%

Earnings Yield

-1.48%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

46.68M

Volume

199.67K

Avg. Volume

436.70K

Financials (TTM)

Gross Profit

$98.46M

Operating Income

-$43.55M

EBITDA

-$39.75M

Operating Cash Flow

$106.01M

Capital Expenditure

-$910.00K

Free Cash Flow

$105.10M

Cash & ST Invst.

$372.32M

Total Debt

$22.55M

Septerna Performance Analysis

Septerna annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 151,000N/A
20242024-12-31USD 1,075,000611.9%
20252025-12-31USD 45,951,0004174.5%
Septerna sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3017963.0%
Q42025-12-3112.2%
Q12026-03-3110.0%
Q22026-06-300.8%
Septerna annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.66N/A
20232023-12-31USD 0.01N/A
20242024-12-31USD -1.62N/A
20252025-12-31USD -1.10-31.7%
Septerna sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30132.1%
Q42025-12-31-233.3%
Q12026-03-3120.8%
Q22026-06-30-52.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$26.75M

+22375.6%

Gross Profit

$26.75M

+22375.6%

Gross Margin

100.00%

N/A

Market Cap

$1.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.95M

N/A

Employees

123

N/A

Net Income

-$13.03M

+47.5%

EBITDA

-$12.06M

+50.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$372.32M

+14.0%

Total Debt

$22.55M

-8.2%

Accounts Receivable

$15.94M

+521.1%

Inventory

$0.00

N/A

Long Term Debt

$20.14M

-10.7%

Short Term Debt

$2.41M

+18.9%

Return on Assets

-4.28%

N/A

Return on Invested Capital

-8.93%

N/A

Free Cash Flow

-$22.18M

-9.0%

Operating Cash Flow

-$22.18M

-9.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FTREFortrea Holdings Inc.
$17.70-4.94%
BCAXBicara Therapeutics Inc. Common Stock
$23.17-0.73%
MRVIMaravai LifeSciences Holdings, Inc.
$7.32-0.68%
KURAKura Oncology, Inc.
$13.25+0.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About SEPN

What is the current price of Septerna?

Septerna is trading at $36.75 per share.

What is the 52-week range for Septerna?

Over the past 52 weeks, Septerna has traded between $13.67 and $51.10.

How much debt does Septerna have?

As of the most recent reporting period, Septerna reported total debt of $22.55M.

How much cash does Septerna have on hand?

Septerna reported $84.66M in cash and cash equivalents in its most recent financial results.

What is Septerna’s dividend yield?

Septerna does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services